Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
Advanced Search
  • May 6, 2021
    - A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott's cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure
    - The trial will utilize Abbott technology including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats
    - Historically, treating patients with both AFib and heart failure has been challenging, with few effective treatments or options to adequately manage both conditions simultaneously
  • Apr 26, 2021
    - New imaging platform merges optical coherence tomography (OCT) with the power of automation using artificial intelligence (AI)
    - Ultreon 1.0 Software helps physicians automatically detect and quantify blood vessel characteristics, giving them better insights for optimal patient treatment
    - Platform offers advanced imaging features when combined with the Dragonfly OpStar™ imaging catheter used to access complex anatomy
  • Apr 19, 2021
    - BinaxNOW is the most studied and widely available rapid antigen test in the U.S. and initially will be available at CVS Pharmacy, Walgreens and Walmart without a prescription
    - Abbott to manufacture tens of millions of BinaxNOW Self Tests per month and can scale capacity upward based on demand
    - The BinaxNOW Self Test will be sold in 2-count packs for an MSRP of $23.99, making it the most affordable over-the-counter (OTC) COVID-19 rapid test available in the U.S.
  • Apr 12, 2021
    - Abbott, Eliud Kipchoge and the NN Running Team collaborate in a partnership to track glucose levels during training and marathons
    - Kipchoge and NN Running Team members will wear Abbott's Libre Sense Glucose Sport Biosensor in upcoming competition at the NN Mission Marathon, the fastest way to the Tokyo Games
    - Built upon the company's world-leading continuous glucose monitoring technology,[i] Abbott's Libre Sense is the world's first glucose biosensor[ii] designed for athletes to help sports performance
  • Apr 8, 2021
    - New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve
    - Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient's complex tricuspid valve anatomy
    - TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions
  • Apr 6, 2021
    - New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding
    - XIENCE is the most used drug eluting stent in the world, and European approval for shorter DAPT is supported by two studies that demonstrated safe treatment of stented patients with one-month or three-month use of DAPT
    - Recent data demonstrate XIENCE with short DAPT does not increase cardiac events and reduces severe bleeding, further confirming the leading safety profile of the XIENCE stent
  • Mar 31, 2021
    - FDA Emergency Use Authorization permits asymptomatic, non-prescription, over-the-counter self use for people with or without symptoms
    - The BinaxNOW COVID-19 Self Test is identical to the professional-use test, used since August 2020, bringing the most studied and widely used rapid antigen test to retail shelves across the country
    - BinaxNOW Self Test will be available nationwide and in large quantities at major food, drug and mass merchandiser retailers nationally and will be priced affordably, similar to common over-the-counter (OTC) tests
    - Together with vaccines, serial testing of asymptomatic people will help restore a sense of safety in everyday settings where people gather
    - Asymptomatic multi-test authorization also applies to BinaxNOW professional-use test
  • Mar 8, 2021
    - Newly FDA-approved system allows a patient to both communicate with a physician and remotely receive stimulation settings in real time regardless of location*
    - NeuroSphere Virtual Clinic utilizes advancements made in digital technology to optimize care through intuitive tools that enhance therapy management
    - Virtual clinic technology can change the treatment approach for patients who live far from necessary medical care or who are burdened by visiting the doctor in person
  • Mar 5, 2021
    -- Abbott's Alinity™ m Resp-4-Plex assay will allow healthcare workers to test for four viruses in one test, a critically important tool as flu presents with similar symptoms
    -- The test helps save on much-needed testing supplies since it allows for testing for all four viruses with one swab
    -- Assay will run on Abbott's most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes
    -- Abbott also received updated EUA for asymptomatic usage of its Alinity m SARS-CoV-2 assay
  • Jan 26, 2021
    - Panbio™ COVID-19 Ag Rapid Test Device supports mass testing in congregate populations of people (mass screening) who are asymptomatic
    - Frequent screening of asymptomatic and symptomatic people helps restore a sense of safety at workplaces, schools, travel and recreational settings, and other places where people gather in large numbers
    - Test is approved for use with a patient-friendly and minimally invasive nasal swab; patients can self-administer sample collection under a healthcare professional's supervision
    - Panbio COVID-19 Ag delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology
    - Test performance in clinical study demonstrated 93.8% sensitivity and 100.0% specificity in asymptomatic people with high viral loads
    - Along with the test, Abbott will offer complementary digital solutions: the NAVICA™ mobile app to allow people to display negative results for proof of testing and Sympheos™ for surveillance management to understand epidemiological trends
    - Since August 2020 to date, Abbott has shipped 200 million Panbio rapid antigen tests to 120 countries worldwide
Show 5102550100 per page
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?